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Background/aim: Colistin is gaining popularity against multidrug-resistant bacteria. The primary concern with colistin is its
nephrotoxicity (NT). The aim of this study was to evaluate the incidence and risk factors for NT and to evaluate the risk factors for
mortality in the toxicity group.
Materials and methods: NT was defined according to the RIFLE criteria. Data of patients who did or did not develop NT were compared.
Positive and negative predictive values, risk ratio, and correlation coefficients were calculated.
Results: NT was seen in 39 patients (70%). Hypoalbuminemia, old age, and the use of vasopressors (VPs) were associated with NT. The
use of VPs had the highest positive predictive value, while age had the highest negative predictive value and risk ratio. The only variable
that was associated with mortality in the toxicity group was VP use.
Conclusion: Aging, hypoalbuminemia, and the use of VPs were shown to be risk factors for NT, while the last of these was the only
significant risk factor for mortality in the toxicity group.
Key words: Colistin, risk factors, nephrotoxicity, mortality

1. Introduction
Over the last few decades, there has been a marked
increase in the incidence of nosocomial infections
caused by multidrug-resistant gram-negative bacteria,
particularly in critically ill patients (1). The shortage of
new antibiotics that specifically target these pathogens
has recently rekindled interest in colistin, a historical
antimicrobial agent, discovered in 1949. The use of colistin
declined from the early 1970s to the early 2000s, due to
its frequent adverse effects, including a high incidence of
nephrotoxicity (NT) (2,3).
It has been reported in many studies that NT was
associated with a poor outcome and high mortality rates
in critical patients (4–6). The reported incidence of NT
varies from 0% to 60% (7–11). The wide range in colistinassociated acute kidney injury (AKI) may be attributed
to inconsistency in how AKI was defined. Most of the
earlier studies did not clearly define the NT. In several
recent studies, NT was defined with specific criteria;
however, varying definitions have complicated study
comparisons (12–17). In 2004, the Acute Dialysis Quality
Initiative Group published their consensus definition
* Correspondence: isilkose66@hotmail.com

for AKI; the Risk, Injury, Failure, Loss, End stage renal
disease (RIFLE) classification is based on the change in the
glomerular filtration rate (GFR), serum creatinine levels,
or urinary output. The RIFLE approach can detect AKI
with high sensitivity and specificity (18). Studies assessing
colistin-associated NT according to RIFLE are scarce in
the literature (19). In this study, we aimed to determine
the risk of renal damage according to the RIFLE criteria
in critically ill patients in the intensive care unit and
secondarily aimed to determine the predictive factors that
facilitate the development of renal damage.
2. Materials and methods
2.1. Study design, setting, and patient population
After approval from the hospital ethics committee, a
retrospective, cohort study was conducted in the 27-bed
intensive care unit (ICU) of a tertiary care hospital (İzmir
Tepecik Training and Research Hospital) in İzmir.
Patients who received intravenous colistin between 1
January 2013 and 1 April 2014 were included in the study.
Patients aged over 18 years and who received intravenous
colistin for at least 72 h were included.
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Patients were excluded if they had been previously
diagnosed with chronic renal disease, regardless of the
need for hemodialysis. Patients with heart failure, liver
disease, and malignancy were also excluded. If a patient
met the inclusion criteria on multiple occasions, only the
first qualifying episode was evaluated.
The product used in this study was colimycin
(colistimethate sodium produced by Koçak Farma,
Turkey) available as 150 mg of colistin base activity per
vial. Colistimethate sodium dosage is regulated as 2.5–5
mg/kg (maximum 300 mg) in patients who do not have
renal insufficiency. We therefore used 5 mg/kg colistin
loading dose followed by two doses of 5 mg/kg (maximum
300 mg) in accordance with the infectious diseases
physician’s recommendations; subsequent dosages were
adjusted according to the serum creatinine (Scr) levels.
The decision to use colistin was based on the
recommendation of an infectious disease specialist and
the results of susceptibility testing given resistance to all
antibiotics apart from colistin.
2.2. Study variables, definitions, and measurements
The electronic medical records for the study patients
were retrospectively reviewed using a standardized data
collection form. The following baseline characteristics of
the patients were collected from the medical records: age,
sex, and the simplified acute physiology score (SAPS II).
Causative microorganisms, coexistence of severe sepsis,
and septic shock were recorded. Severe sepsis and septic
shock were defined according to the Surviving Sepsis
Guidelines (20). Concomitant use of other nephrotoxins
(nephrotoxic antimicrobials, loop diuretics, intravenous
dye, nonsteroidal antiinflammatory drugs (NSAID),
angiotensin-converting-enzyme (ACE) inhibitors, and

calcineurin inhibitors), use of vasopressors (VPs), serum
albumin levels, and duration of colistin therapy were
recorded. NT was determined by the RIFLE criteria.
RIFLE has three severity classes, which were assessed by
relative changes in either Scr or the GFR from a baseline
value, or by a decrease in urine output at a predetermined
time interval. The two outcome criteria were defined by
the duration of the loss of kidney function, which was
assessed at the 4th week (loss) and 3rd month (end-stage
kidney disease) (Table 1).
If data were not available for assessing the GFR at the
4th week and 3rd month, due to patient death or discharge,
only the acute degree of NT was considered. The need for
renal replacement therapy was also recorded.
2.3. Statistical analysis
IBM SPSS version 22.0 (IBM Corp, Somers, NY, USA) was
used for statistical analysis. Normality was assessed using
the Kolmogorov–Smirnov test. Continuous normally
distributed data, expressed as mean ± SD, were compared
using an independent sample t-test. Nonnormally
distributed data, expressed as median and interquartile
range (IQR), were compared using the Mann–Whitney
U-test. Categorical data are expressed as number (n) and
percentage (%) of events and compared by the Pearson
chi-square or the Fisher exact test. The data were analyzed
at a confidence level of 95%. A P-value of less than 0.05 was
considered statistically significant.
The receiver operating characteristic (ROC) curve
was used to evaluate the cut-off values of the independent
numerical variables with a P-value less than 0.05. The
Youden’s indices were calculated and the maximum
Youden’s index was used as the cut-off value in the ROC
curve. Cut-off values for nephrotoxicity and mortality

Table 1. RIFLE criteria.
GFR criteria

Urine output criteria

Risk

Increased SCr × 1.5
GFR decrease > 25%

<0.5 mL/kg/h × 6 h

Injury

Increased SCr × 2
GFR decrease > 50%

<0.5 mL/kg/h × 12 h

Failure

Increased SCr × 3,
GFR decrease > 75%
SCr ≥ 4 mg/dL with an acute rise > 0.5 mg/dL

< 0.3 ml/kg/h × 24 h, or anuria × 12 h

Loss

Persistent ARF or loss of function > 4 weeks

ESRD

ESRD > 3 months

GFR: Glomerular filtration rate,
SCr: Serum creatinine,
ARF: Acute renal failure,
ESRD: End stage renal disease
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were separately analyzed. Area under the curve (AUC)
values of 0.9–0.99, 0.8–0.89, 0.7–0.79, 0.6–0.69, and <0.6
were considered excellent, good, reasonable, poor, and
failed discrimination, respectively.
According to the cut-off values cases were divided into
two groups, high-risk group and low-risk group and a
chi-squared test was performed subsequently. Prediction
accuracy was evaluated using positive predicted value
(PPV) and negative predicted value (NPV). Correlation
coefficient (phi), relative risk (RR), and odds ratio (OR)
were also calculated.
3. Results
Over the study period, 1089 patients were admitted to our
ICU. Of these, 71 received colistin. In total, 71 patients
were evaluated and 56 met all inclusion/exclusion criteria
as 15 patients were excluded because 10 had chronic
kidney disease and 5 received colistin for less than 72 h
(Figure). SAPS II, baseline creatinine levels, and length of
ICU stay were nonnormally distributed for NT. Skewness
and kurtosis were 0.88 (SE = 0.39) and 1.14 (SE = 0.63) for
SAPS II, 0.84 (SE = 0.32) and 0.95 (SE = 0.63) for creatinine
levels, and 2.87 (SE = 0.32) and 10.44 (SE = 0.63) for ICU
stay, respectively.
Assessing mortality in patients who developed NT,
age, baseline creatinine levels, length of ICU stay, and
time to NT were nonnormally distributed. Skewness and
kurtosis were –1.048 (SE = 0.378) and 1.071 (SE = 0.741)
for age, 0.83 (SE = 0.38) and 0.92 (SE = 0.74) for creatinine
levels, 2.60 (SE = 0.38) and 8.16 (SE = 0.74) for ICU stay,
and 1.33 (SE = 0.38) and 1.51 (SE = 0.74) for time to NT,
respectively.
3.1. Descriptive data
Of the 56 patients, 29 were male (51.8%). The median
(IQR) SAPS II score was 47.50 (42.25–60.00). The mean
± SD of age and albumin level was 64.09 ± 20.89 and 2.28

± 0.49, respectively. In total, 38 (67.9%) were medical
patients, 11 (19.6%) were admitted after surgery, and seven
(12.5%) were trauma patients.
A. baumannii was the only detectable microorganism
in 52 patients. Four patients, who had refractory fever and
other evidence of infection, received colistin empirically.
While the most frequent infection was ventilatorassociated pneumonia (57.7%), bloodstream infections
(25.0%), surgical site infections (15.4%), and urinary tract
infections (1.9%) were also observed.
Severe sepsis and septic shock were seen in 18
patients. The mean ± SD duration of colistin therapy
was 11.54 (±5.58) days. During the colistin therapy, nine
patients were exposed to other nephrotoxic agents. Six
patients received other nephrotoxic antibiotics. The most
frequent concomitant use of nephrotoxic antibiotics was
vancomycin in three patients. Two patients received
aminoglycoside, and one patient received vancomycin
and aminoglycoside in combination. Two patients were
administered NSAIDs, while radiocontrast medium was
given to one patient. Twenty patients required VP therapy.
3.2. Outcome data
Thirty-nine (70%) patients developed NT (toxicity group),
leaving 17 (30%) without NT (nontoxicity group). Of the
39 patients, 14 (25%) were in the risk group, nine (16%)
were in the injury group, and 16 (29%) were in the failure
group. Twelve patients required renal replacement therapy.
Sadly, 14 patients with NT died before colistin therapy
ended. Among the survivors with NT (n = 25), NT did not
resolve in five patients.
3.3. Main results
NT was seen after a median (IQR) of 5.0 (3.0–7.0) days
(min–max: 2–16). ICU mortality was slightly higher in
the NT group (P = 0.047). The length of ICU stay was
also higher. There was no significant difference between
the groups with and without NT for SAPS II scores, sex,

Records of 1089 patients admitted to the ICU were reviewed !!
1018 patients were excluded (did not receive colistin)
Records of 71 patients screened
5 patients were excluded ( colistintherapy < 72 h)
10 patients were excluded (had CKD)
Records of 56 patients included

Figure. Flow diagram of study screening.
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admission diagnosis, baseline creatinine levels, coexistence
of sepsis, and exposure to nephrotoxic factors. The mean
age and frequency of VP use was significantly higher in
the toxicity group, while albumin levels were significantly
lower (Table 2). ROC curves were generated to determine
the clinically relevant cut-off for age and albumin levels
as a predictor of NT. Analysis of the ROC curves showed
that the discriminative ability was reasonable for albumin
(AUC = 0.70, 95% CI = 0.541–0.856) with a cut-off value
of 2.65 mg/dL and poor for age (AUC = 0.64, 95% CI =
0.468–0.819) with a cut off value of 46 years. NT rates were
79.5% in older patients compared with 33.3% in younger
patients. Similarly, patients with lower albumin levels had
higher NT rates (81.1%) than patients with higher levels
(52.6%).
The use of VPs had a PPV and NPV for NT of 90% and
41.7% (RR = 1.543), respectively, while low albumin levels
had values of 81.1% and 52.6% (RR = 1.712) and older age
79.5% and 66.7% (RR = 2.386), respectively.
No variables, with the exception of VP use, showed
a statistically significant difference among patients who
survived and those who did not (Table 3).
The risk of mortality in the NT group who received
VPs was 1.65 times that of patients that did not receive
VPs. Receiving VPs had a PPV of 94% for mortality. The

correlation coefficient (phi), PPV, NPV, RR, and ORs of
the predictors are listed in Table 4.
4. Discussion
The rate of nephrotoxicity in intensive care patients
who used colistin, which is the primary objective of our
study, was determined as 70%. This rate was higher than
in previous studies. This may be due to the fact that our
study was performed in a 3rd stage intensive care unit, the
height of the saps2 scores, and the excess of accompanying
diseases of the patients. Various criteria have been used
to identify NT. The sensitivity of the RIFLE criteria in
detecting AKI is high and it may have also contributed to
the high incidence of NT.
The RIFLE criteria have been suggested for comparison
of NT among different studies (21,22). Hartzell et al.
demonstrated a NT rate of 45% in their cohort using the
RIFLE criteria. However, their study group consisted of
relatively young patients with lower comorbidities (21).
Temocin et al. reported a similarly low NT rate (48%);
however, they did not specify the disease severity scores or
comorbidities of patients, which may contribute to NT (23).
Similar to our results, Omrani et al. reported higher
rates (71%) of NT; however, their study population was
younger and not all were ICU patients (24).

Table 2. Characteristics of patients with and without nephrotoxicity.
Whole cohort (56)

No NT (17)

NT (39)

P

64.09 ± 20.89

53.35 ± 25.27

68.77 ± 17.00

0.031

Male b

29

8

21

0.640

SAPS c

47.50 (42.25–60.00)

46.00 (43.50–50.00)

48.00 (41.00–64.00)

0.276

Medical
Surgery
Trauma

38
11
7

12
1
4

26
10
3

0.093

Albumin a

2.28 ± 0.49

2.51 ± 0.55

2.18 ± 0,44

0.019

Cr level

0.95 (0.7–1.2)

0.80 (0.55–1.10)

1.00 (0.70–1.30)

0.183

VAP / BSI
UTI / SSI

30 / 13
1/8

6/4
1/4

24 / 9
0/4

0.199

Sepsis

18

6

12

0.739

NT agentsb

9

3

6

0.832

VPs b

20

2

18

0.016

37.50 (21.50–73.00)

28.00 (18.50–48.50)

43.00 (29.00–90.00)

0.038

37

8

29

0.047

Age

a

c

ICU day

c

Mortality

b

a: Independent t test, mean (SD);
b: Pearson chi square test (exact);
c: Mann–Whitney U test, median (IQR)
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Table 3. Characteristics of nephrotoxicity group with and without mortality.
No mortality (10)

Mortality (29)

P

63.50 (36.50–73.00)

73.00 (61.00–78.00)

0.074

6

15

0.726

SAPS II c
Medical
Surgery
Trauma
Albumin level c

52.00 ± 10.61
6
2
2
2.30 ± 0.53

51.93 ± 16.25
20
8
1
2.14 ± 0.40

0.990

Baseline Cr

0.85 (0.50–1.15)

1.10 (0.75–1.35)

0.175

2

10

0.462

1

17

0.008

Nephrotoxic agents

2

4

0.639

NT day

6.0 (3.5–13.25)

5.0 (3.0–7.0)

0.256

Age

a

Male sex

b

a

Sepsis b
VPs b
b

a

0.280
0.323

a: Mann–Whitney U test, median, (IQR)
b: Pearson chi square test (exact)
c: Independent t test, mean ± SD
Table 4. Correlation coefficient (phi), predictive values, relative risks, and odds ratios of predictors for nephrotoxicity and mortality in
the nephrotoxicity group.

NT
Mortality

PPV

NPV

RR

OR

Phi

P

Alb

0.81

0.53

1.71 (1.04–2.82)

4.76 (1.41–16.13)

0.347

0.014

VPs

0.90

0.42

1.54 (1.13–2.11)

6.43 (1.29–2.11)

0.330

0.016

Age

0.79

0.67

2.39 (1.06–5.39)

7.78 (1.91–31.73)

0.412

0.004

VPs

0.94

0.42

1.65 (1.12–2.23)

12.75 (1.42–114.4)

0.426

0.008

NPV: Negative predictive value
PPV: Positive predictive value
RR: Relative risks
OR: Odds ratios
Alb: Albumin

Some recent studies have investigated the risk factors
for colistin-associated NT (8,21,24–34). Results from
previous studies are given with their significance levels in
Table 5. These studies show different results for each risk
factor.
Factors that facilitate the development of nephrotoxicity
in intensive care patients using colistin, a secondary
objective of our study, were older age, lower albumin levels,
and the use of vasopressors. These factors were compatible
with previous studies. On the other hand, we also found
that sepsis and septic shock, which had different outcomes
in the literature, had no effect on nephrotoxicity.

Age was the most significant predictor in our study.
It has the highest RR and NPV among all predictors for
NT. Balkan et al. reported NT rates similar to ours in
similar age groups (28). Other studies with large numbers
of patients also found age to be an important risk factor
(26,30). However, in a relatively young cohort of patients,
no significant correlation between age and NT was
shown. This may be explained by the effect of age on renal
functional reserve.
Different albumin levels have been investigated in
various studies to determine hypoalbuminemia. Kim et
al. found that albumin levels lower than 3.2 g/dL were
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Table 5. Reference numbers of studies evaluating colistin associated NT.
P < 0.05

P > 0.05

Age

24, 25, 26, 28, 30

8, 21, 27, 29, 31, 32

Sex

-

8, 21, 24, 25, 26, 27, 28, 29, 31, 33

Body weight

25

24, 26, 27, 28

Disease severity

29 (SAPS II)

21, 25, 26, 27, 28, 30 (APACHE II)

26, 28
25, 31
27

8, 24, 31, 33
8, 24, 27, 28
8, 28

Dose

-

8, 21, 24, 25, 28, 30, 32, 34

Duration

21, 26

8, 24, 27, 28, 29, 34

Creatinine

-

21, 27, 28

Severe sepsis

26, 29

26, 31, 34

Albumin

8, 24, 26

25, 28

VPs

-

21, 27, 31

Aminoglycoside

33

21, 24, 26, 27, 28, 33, 34

NSAID

26

21, 24, 27, 28, 33

Contrast media

27, 34

28, 21, 24, 33

Diuretics

26, 31

21, 24, 27, 33, 34

Comorbidity

CCI
DM
HT

CCI: Carlson comorbidity index

associated with higher NT rates. However, in another
study, which defined hypoalbuminemia as levels lower
than 2.0 g/dL, no significant difference was observed.
Studies comparing the mean albumin levels had different
results. We observed a significant correlation between
albumin levels and NT rates; ROC curve analysis showed
an optimal cut-off value of 2.65 g/dL. The use of VPs was
the third and last predictor of NT in our study. It had the
highest PPV among the three predictors. In the literature,
there are not sufficient data to use VP as a risk factor for
colistin-associated NT. In a small cohort 40% of patients
who had developed NT had received VPs, whereas in
the nontoxicity group none of the patients had used VPs
(20). However, other studies did not report any significant
relationship between NT and the use of VPs (21,27,31).
Although sepsis is evaluated as one of the most
common contributing factors in AKI of critical illness, the
data are insufficient to conclude that colistin-associated
NT is related to sepsis or septic shock.
Two large studies demonstrated that patients with
septic shock had a higher incidence of NT (26–29).
However, a prospective study did not identify septic
shock as a risk factor for sepsis (34). Similarly, Pogue et
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al. reported no significant correlation between sepsis and
NT rates (31).
In the present study, we did not assess severe sepsis
and septic shock separately, and we found no difference
between the groups who did or did not have severe sepsis/
septic shock. The association between NT and mortality
has been discussed in earlier studies. Falagas et al. reported
in their large cohort that creatinine change during colistin
therapy was associated with mortality (aOR = 0.21) (11).
In a recent study, no correlation was observed between
mortality and NT; however, the number of patients in the
NT group was small (n = 6) (35).
We could not find any published data assessing the
risk factors for mortality among patients with colistinassociated nephropathy. The only risk factor for mortality
we identified was the use of VPs, which had a PPV as high
as 94%.
5. Limitations
One of the limitations of our study was the relatively small
number of patients for logistic regression analysis. As such,
we were unable to conclude whether or not the risk factors
for NT would be statistically significant in the model. In
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addition, we did not assess severe sepsis and septic shock
separately. Although there was no statistically significant
relationship between sepsis and NT, patients who received
VPs had significantly higher NT rates. Because we had no
data on the reason for VP use, we were unable to determine
if it was associated with septic shock or other shock states.

Therefore, we cannot draw any conclusions regarding the
correlation between septic shock, VP use, and NT.
In conclusion, older age, hypoalbuminemia, and the
use of VPs can contribute to colistin-associated NT in ICU
patients. The use of VPs was identified as the only factor
associated with mortality in patients who developed NT.
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